AU Patent

AU2021348477B2 — Csf1r kinase inhibitor and use thereof

Assigned to Shanghai Institute of Materia Medica of CAS · Expires 2023-12-21 · 2y expired

What this patent protects

Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.

USPTO Abstract

Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021348477B2
Jurisdiction
AU
Classification
—
Expires
2023-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Materia Medica of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.